Cabaletta Bio Reports Strong Rese-cel Data Across Autoimmune Portfolio, Advances Registrational Plans
CABA has more than doubled off its 52-week low of $1.26.
Summary
Cabaletta Bio released encouraging clinical data for its rese-cel therapy in autoimmune diseases, outlining plans for registrational studies in systemic sclerosis and myositis, and advancing its preconditioning-free program.
Key Events · Product Development and Regulatory · CABA
-
Positive Clinical Data for Myositis
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint, with responses maintained for up to 1.5 years. The first juvenile dermatomyositis patient also showed a moderate response maintained for 32 weeks.
-
Systemic Sclerosis Advances to Registrational Program
Systemic Sclerosis (SSc) is announced as a second pivotal indication, with a single-arm registrational study for SSc-associated interstitial lung disease anticipated to start in 4Q26.
-
Encouraging PC-Free Lupus Findings
Initial data from preconditioning-free (PC-free) rese-cel in lupus patients showed deep B cell depletion in one of two patients, suggesting potential for broader patient access and improved experience.
-
Clear Regulatory Pathway
The company plans a Biologics License Application (BLA) submission for adult and juvenile dermatomyositis in 2H27 and will report topline data from the DM/ASyS registrational cohort in mid-2027.
Analysis · CABA · Life Sciences
Cabaletta Bio announced comprehensive positive clinical data for its rese-cel therapy across multiple autoimmune diseases, including dermatomyositis, systemic sclerosis, and lupus. The data shows high response rates and a favorable safety profile, supporting the company's strategy to advance rese-cel into registrational trials. This update is critical for the company's long-term prospects, especially following recent dilutive financing and a 'going concern' warning, as it provides a clear path towards potential regulatory submissions and commercialization.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CABA was trading at $3.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $600M. The 52-week trading range was $1.26 to $4.23. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.